Regulus Therapeutics Inc.
RGLS
Classifica tra le azioni
#17368
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prezzo delle azioni
$8.16
Ultima sincronizzazione: 2025-06-26
Capitalizzazione di mercato
$234.57M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-88.86%
Paese
US
Scambia Regulus Therapeutics Inc. (RGLS)
Categoria
Healthcare
EPS per Regulus Therapeutics Inc. (RGLS)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Regulus Therapeutics Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Regulus Therapeutics Inc. da 2026 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
